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  ABSTRACT 
  Objective      Infusion reaction is a major adverse event 
in patients with rheumatoid arthritis (RA) treated with 
inﬂ  iximab. The possible factors including Fcγ receptor 
(FcγR) polymorphism associated with the development of 
infusion reactions in patients with RA receiving inﬂ  iximab 
were prospectively examined.   
  Methods      96 patients with RA were enrolled and 
scheduled to receive inﬂ  iximab at a dose of 3 mg/kg at 
weeks 0, 2 and 6 and every 8 weeks thereafter. Genetic 
polymorphisms for FcγR were examined in   FCGR3A  
176F/V and   FCGR3B   NA1/2 alleles by allele-speciﬁ  c PCR 
analysis.  
  Results      An infusion reaction was observed in 17 
patients (18%) during 52 weeks of treatment with 
inﬂ  iximab. The   FCGR3B   NA1/NA1 genotype was found 
in 75% of the patients with infusion reactions and in only 
37% of those without (p=0.01), whereas the   FCGR3A  
176F/V genotype was equally distributed in the patients 
with or without infusion reactions. Glucocorticoids were 
used in 53% of the patients who developed an infusion 
reaction and in 80% of those without an infusion reaction 
(p=0.02). A multivariable logistic regression model 
showed that the   FCGR3B   NA1/NA1 genotype and use of 
glucocorticoids at baseline could be used as independent 
predictive factors for infusion reactions (OR 6.1 (95% 
CI 1.9 to 24.3) and OR 0.26 (95% CI 0.08 to 0.84), 
respectively). The presence of anti-inﬂ  iximab antibody 
during inﬂ  iximab treatment was also associated with 
infusion reactions.   
  Conclusion     FCGR3B   NA1/NA1 genotype, use of 
glucocorticoids and the presence of anti-inﬂ  iximab 
antibody accounted for nearly all patients with RA who 
developed  infusion  reactions.      
  INTRODUCTION 
  Biological agents targeting a speciﬁ  c molecule pro-
vide an effective means for therapeutic management 
of rheumatoid arthritis (RA) due to their speciﬁ  city 
and powerful functional capabilities, which has 
resulted in a paradigm shift in the treatment strat-
egy of this disease.    1   –    4    Despite their effectiveness, 
several adverse drug reactions associated with the 
use of biological agents have been identiﬁ  ed, such 
as opportunistic infections and the development of 
hypersensitivity/infusion reactions. For example, 
approximately 10–23% of patients with RA expe-
rience infusion reactions (including fever, malaise, 
headaches, erythema and urticaria) to inﬂ  iximab, 
a chimeric monoclonal IgG1 antibody against 
tumour necrosis factor α (TNFα), in combination 
with methotrexate (MTX).    5   –    9    Although much less 
frequent, severe infusion reactions such as anaphy-
lactic/anaphylactoid symptoms are also observed 
in patients with RA.    8    Despite the fact that most of 
these reactions are only mild or moderate in sever-
ity, they may lead to discontinuation of treatment, 
which is of particular concern and highly relevant 
to daily clinical practice.    9    It is tempting to speculate 
that biological agents may induce these reactions in 
a portion of susceptible patients by causing hyper-
sensitivity to the given biological agents,    10    in part 
through the immunogenicity of the agents or by 
direct effects on cellular functions through the Fc 
portion of the products.    11    
  The Fc portion of IgG-based biological agents 
can bind to Fcγ receptors (FcγR) for clearing the 
agents and even affecting cellular functions includ-
ing phagocytosis, antibody-dependent cellular 
cytotoxicity and neutrophil activation.    12    FcγR con-
sist of three major families which are encoded by 
eight genes:   FCGRIA  ,   FCGRIB  ,   FCGR1C  ,   FCGR2A  , 
  FCGR2B  ,   FCGR2C  ,   FCGR3A   and   FCGR3B  . 
Functional allelic polymorphisms leading to dis-
tinct effector capabilities have been identiﬁ  ed in the 
receptors FcγRIIa, FcγRIIb, FcγRIIIa and FcγRIIIb.    12    
  Since the   FCGR2A   131 H/R allele strongly inﬂ  u-
ences the ability of FcγRIIa to bind human IgG2 
but has only limited effects on IgG1 and IgG3 
binding,    12    we focused on the   FCGR3A   158F/V and 
  FCGR3B   NA1/NA2 alleles and prospectively exam-
ined the possible association of these   FCGR   alleles, 
development of antibody to inﬂ  iximab and clinical 
parameters with development of infusion reactions 
to inﬂ  iximab in patients with RA.   
  METHODS 
  Patients  and  treatment 
  Consecutive patients with RA who fulﬁ  lled  the 
1987 revised criteria of the American College of 
Rheumatology for the classiﬁ   cation of RA    13    and 
satisﬁ   ed the Japanese guidelines for the use of 
anti-TNF biological agents    14    were invited to par-
ticipate in the study. Ninety-six patients showing 
incomplete response to MTX were enrolled after 
obtaining their written informed consent. The 
2008 Declaration of Helsinki and the 2008 Ethical 
Guidelines for Clinical Research by the Japanese 
Ministry of Health, Labour and Welfare were 
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  Determination  of  FcγR polymorphisms 
  Heparinised venous blood was collected from patients and 
chromosomal DNA was isolated using phenol–chloroform 
extraction. Genetic polymorphisms for FcγR were examined in 
  FCGR3A   176F/V and   FCGR3B   NA1/2 alleles by allele-speciﬁ  c 
PCR analysis, as previously described.    16        17    PCR products were 
separated on 3% agarose gels and visualised under ultraviolet 
light using a photoimager.   
  Statistical  analysis 
  Baseline variables of patients with RA were analysed for asso-
ciation with development of infusion reactions using a χ² test 
for categorical variables and Student t test for continuous vari-
ables. Univariate logistic regression analysis was used to screen 
for potential predictor variables, and a stepwise selection pro-
cess was used to generate a multivariate model for potential 
predictors of infusion reactions. All statistical analyses were per-
formed on a Mac OS X platform (Sun Microsystems, Palo Alto, 
California, USA) using JMP Version 8.0.2.     
  RESULTS 
    Clinical characteristics of the patients with RA who 
developed infusion reactions 
  As shown in   table 1  , the development of infusion reactions, con-
comitant medications and the continuation of inﬂ  iximab varied 
in individual patients. The observed infusion reactions were 
typically mild or moderate and included chills, fever, erythema 
and urticaria; however, one patient developed a severe anaphy-
lactoid reaction and hypotension. Prior to the study, this patient 
had been enrolled in a clinical trial for inﬂ  iximab, and the severe 
infusion reaction developed in this study after the second infu-
sion, which represented a 3-year interval since he last received 
inﬂ  iximab in the clinical trial. The most common manifesta-
tion in the patients was skin eruption (n=10), followed by fever 
(n=3), nausea/vomiting (n=3) and headache (n=2). Although 
these manifestations were not considered severe, nearly all of 
strictly followed in this study. The patients were scheduled to 
receive inﬂ  iximab at a dose of 3 mg/kg at weeks 0, 2, 6 and sub-
sequently every 8 weeks added to MTX at the Saitama Medical 
Center between September 2003 and March 2008. The manage-
ment of infusion was performed using a previously reported 
protocol    15    approved by the University Institutional Review 
Board. We did not perform any premedication including hista-
mine antagonists, paracetamol and additional glucocorticoids 
until the ﬁ  rst infusion reaction developed in individual patients. 
Blood samples were taken for genotyping before initiation of 
inﬂ  iximab, and anti-inﬂ  iximab antibody (AIA) was measured at 
each infusion visit during the 52-week study.   
  Assessment  of  efﬁ  cacy and safety 
  Patients were followed up longitudinally with examinations at 
baseline and at each regular infusion visit and emergency visit 
during the 52-week study. To monitor disease activity and dis-
ability, the 28-joint Disease Activity Score based on C reactive 
protein (DAS28-CRP) and serum levels of CRP, matrix metal-
loproteinase-3 (MMP-3) and Health Assessment Questionnaire-
Disease Index (HAQ-DI) were determined. The attending 
physicians recorded any adverse drug reactions at baseline, 
at each regular infusion visit and emergency visit during the 
52-week study period.   
  Measurement  of  AIA 
  AIA was measured using an ELISA kit (Immunodiagnostik, 
Bensheim, Germany). Brieﬂ  y, serum samples were diluted with 
phosphate buffered saline (PBS) and added to 96-well plastic 
plates coated with the F(ab)  2   portion of inﬂ   iximab to avoid 
interference with rheumatoid factor (RF). After incubating over-
night at 4°C, the wells were washed with PBS and horseradish 
peroxidase-labelled inﬂ  iximab was added. After incubation for 
60 min, the plates were extensively washed with PBS, followed 
by addition of substrates into each well. The OD  450  −OD  620   was 
recorded using an ELISA reader.   
  Table  1         Demographic and clinical characteristics of patients with infusion reactions   
 No   Gender 
 Age 
(year) 
 Duration 
(month) 
 DAS28  at 
baseline 
 CRP 
(mg/dl) 
 RF 
(IU/ml)   ANA  (×) 
 MMP-3 
(ng/ml)   HAQ-DI 
 Clinical 
manifestation 
 Time  of 
infusion 
reaction 
(weeks) 
 MTX 
(mg/week) 
 PRED 
(mg/day) 
 Adherence 
to inﬂ  iximab 
1 F 51 60 6.9 7.8 12 160 346 2.6 Chills, fever, dyspnoea 38 13 0 Discontinue
2 F 52 9 6.6 6.9 444 0 188 2.1 Hot ﬂ  ushes, headache, 
subfever
1 8 10 Continue
3 M 69 624 5.7 3.9 191 80 180 1.8 Anaphylactoid reaction, 
hypotension
2 (after 
3-year 
interval)
6 5 Discontinue
4 F 40 50 4.8 2.9 864 80 200 1.3 Urticaria 14 12.5 0 Discontinue
5 F 50 97 3.5 0.3 23 80 121 0.3 Urticaria 30 10.5 5 Discontinue
6 F 68 48 4.5 3.2 42 80 95 0.13 Erythema 14 8 0 Discontinue
7 M 65 240 4.8 2.8 1080 320 85 2.6 Hot ﬂ  ushes, headache, 
nausea
14 10 3 Discontinue
8 F 52 255 5.7 3.3 845 160 191 1.3 Erythema 30 8 0 Discontinue
9 F 31 29 4.8 0.1 17 1280 98 0.5 Nausea 44 8 0 Discontinue
10 F 60 210 4.2 1.8 250 80 359 0.6 Urticaria 14 8 0 Discontinue
11 F 52 168 3.5 0.3 15 1280 121 0.3 Urticaria 2 6 0 Discontinue
12 F 57 360 6.6 6.4 98 1280 360 1.5 Erythema 14 6 4 Discontinue
13 F 33 21 6.6 5.2 122 80 612 1.1 Erythema 14 10 4 Continue
14 F 37 9 7.5 5.6 <5 0 280 1.9 Fever 14 6 10 Discontinue
15 F 37 60 4.3 1.4 446 80 ND 0.8 Erythema 30 8 0 Continue
16 F 63 4 7.4 11.0 1060 80 412 2.5 Nausea, vomiting 14 8 7.5 Discontinue
17 F 64 134 6.0 0.8 <5 1280 253 1.9 Erythema 22 6 0 Discontinue
      ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disease Index; MMP, matrix metalloproteinase; 
MTX, methotrexate; ND, not done; PRED, prednisolone; RF, rheumatoid factor.     
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6%, respectively, of patients who developed infusion reactions, 
which is much lower than the 37% and 27%, respectively, of 
those without reactions. Analyses conﬁ  rmed that the distribu-
tion of the   FCGR3B   genotypes between patients with and with-
out infusion reactions was signiﬁ  cantly different (p=0.01). On 
the other hand, such differences in distribution of the   FCGR3B   
genotypes were not observed between those with and without 
adherence to inﬂ  iximab. 
  The presence of AIA during each visit was found to be posi-
tive in 19% of the patients. The development of AIA was signiﬁ  -
cantly higher in patients with infusion reactions than in those 
without (65% and 9%, respectively, p<0.001), whereas no dif-
ference was observed in patients with or without adherence to 
inﬂ  iximab (15% and 22%, respectively, p=0.40).   
    Potential predictive variables for infusion reactions 
  The impact of the presence or absence of risk factors identiﬁ  ed 
on the development of infusion reactions is summarised and 
compared in   ﬁ  gure 1  . In order to create a multivariate model 
of potential predictors of infusion reactions, we ﬁ  rst screened a 
series of baseline variables which included age, gender, duration 
of RA, DAS score, levels of CRP, MMP-3, HAQ-DI, RF and anti-
nuclear antibody, doses of MTX and prednisolone equivalent, 
glucocorticoid use and   FCGR3A   V/V+V/F and   FCGR3B   NA1/
NA1 genotypes by univariate logistic regression. As shown in 
  table 4  , the   FCGR3B   NA1/NA1 genotype and use of glucocor-
ticoids were signiﬁ   cant predictive variables, consistent with 
the above analyses. Even by stepwise selection, these variables 
were identiﬁ  ed as signiﬁ  cant factors associated with infusion 
reactions (data not shown).     
  We next subjected these two variables to multivariate logis-
tic regression analyses which allowed for differences in patients 
with or without infusion reactions to be adjusted. From these 
analyses, the   FCGR3B   NA1/NA1 genotype and use of glucocor-
ticoids were ﬁ  nally identiﬁ  ed as signiﬁ  cant independent vari-
ables associated with the development of infusion reactions. 
The ORs of the   FCGR3B   NA1/NA1 genotype and the use of 
glucocorticoids were 6.1 (95% CI 1.9 to 24.3, p=0.002) and 0.26 
(95% CI 0.08 to 0.84, p=0.025), respectively (  table 5  ).   
  Finally, we examined the potential additive effect of the three 
identiﬁ   ed factors on the development of infusion reactions. 
Patients with RA with only one factor had a rate of infusion 
the patients (15 of 17) discontinued inﬂ  iximab due to the devel-
opment of these infusion reactions.     
    Demographics and clinical characteristics of the patients 
  As shown in   table 2  , the mean age of the patients was 54 years 
and 83% were women. The mean disease duration was 8 years, 
RF positivity was 90%, the mean DAS28 score was 5.2 and the 
mean serum HAQ-DI level was 1.5, suggesting that the patients 
with RA enrolled in this study were established, active and 
disabled.   
  There were no signiﬁ  cant differences in the demographics 
and clinical characteristics between patients who developed 
infusion reactions and those who did not, with the exception 
of the concomitant use of glucocorticoids. Glucocorticoids were 
used in 53% of patients with infusion reactions compared with 
80% of patients without infusion reactions. In contrast, no sig-
niﬁ  cant differences in the demographics and clinical characteris-
tics between patients who continued inﬂ  iximab and those who 
discontinued its use were demonstrated in this study.      
  F c γR polymorphism 
  Allele distributions in the patients with RA for the   FCGR3A   
176F/V and   FCGR3B   NA1/NA2 polymorphisms are sum-
marised in   table 3  . In this cohort of patients, the distribution of 
the   FCGR3A   high-afﬁ  nity genotype V/V was 6% whereas the 
V/F and F/F genotypes were observed with a frequency of 48% 
and 46%, respectively. The occurrence of the V/V genotype was 
slightly lower than in the healthy Japanese population (8.6%).    18    
The V/V genotype was enriched in patients with RA with infu-
sion reactions (12%) over those without such reactions (5%), 
but the difference was not signiﬁ  cant. The distributions of the 
genotypes for the   FCGR3A   176F/V allele between patients with 
and without adherence to inﬂ  iximab were comparable.   
  The high-afﬁ  nity genotype of   FCGR3B   (NA1/NA1) was the 
most prevalent genotype in the patients with RA (44%), while 
the NA1/NA2 and NA2/NA2 genotypes were found in 33% and 
23% of patients, respectively. The   FCGR3B   NA1/NA1 geno-
type was found in 70% of patients with infusion reactions but 
was present in only 37% of patients without infusion reactions, 
indicating that this genotype is associated with the develop-
ment of infusion reactions. In contrast, the low-afﬁ  nity geno-
types NA1/NA2 and NA2/NA2 were only observed in 18% and 
  Table  2         Patient characteristics and inﬂ  iximab-related outcome   
 Subject   Total  (n=96) 
  Infusion reaction during 52 weeks 
 p  Value 
  Adherence to inﬂ  iximab during 52 weeks 
 p  Value   Yes  (n=17)   No  (n=79)   Continued  (n=46)   Discontinued  (n=50) 
Age (years) 54±13 52±12 55±13 0.82 56±12 53±14 0.16
Female (%) 83 88 81 0.55 89 78 0.14
Disease duration (years) 8±9 11±14 8±8 0.18 8±7 9±10 0.57
RF positivity (%) 90 88 90 0.84 91 88 0.60
RF (IU/ml) 213±321 324±394 189±300 0.10 190±319 145±324 0.79
ANA positivity (%) 32 41 30 0.39 30 34 0.71
ANA titre (×) 273±616 377±150 251±69 0.20 341±813 211±346 0.16
Stage I+II (%) 44 47 43 0.46 33 43 0.05
Class 1+2 (%) 65 82 62 0.18 65 64 0.53
DAS28 5.2±1.3 5.4±1.6 5.2±1.3 0.69 5.1±1.5 5.4±1.2 0.22
CRP (mg/dl) 4.0±3.3 4.1±3.0 3.9±3.4 0.87 3.5±3.4 4.3±3.2 0.26
MMP-3 (ng/ml) 293±287 146±38 301±309 0.36 340±374 255±189 0.17
HAQ-DI 1.5±0.8 1.4±0.9 1.5±0.7 0.76 1.5±0.8 1.5±0.7 0.96
MTX dose (mg/week) 8±3 8±2 8±3 0.35 8±4 9±3 0.95
Use of glucocorticoids (%) 75 53 80 0.02* 74 76 0.81
Glucocorticoid dose (mg/day) 4±3 3±4 5±3 0.92 5±4 4±3 0.19
      ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disease Index; MMP, matrix metalloproteinase; 
MTX, methotrexate; RF, rheumatoid factor.     
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reactions of 11%, whereas those with two or three factors 
had rates of 53% and 100%, respectively (see ﬁ  gure in online 
supplement), demonstrating that these three factors additively 
account for the infusion reactions to inﬂ  iximab observed in the 
96 patients with RA examined in this study.     
  DISCUSSION 
  The results of this study show that the high-afﬁ  nity   FCGR3B   
NA1/NA1 genotype and the absence of glucocorticoid use at 
baseline are the main independent predictive factors for the 
development of infusion reactions to inﬂ   iximab in Japanese 
patients with RA. This study is the ﬁ  rst to demonstrate a role 
for the   FCGR3B   NA1/NA1 genotype in infusion reactions to 
inﬂ  iximab. 
  Mild to moderate and severe infusion reactions were 
observed in 18% and 1%, respectively, of the Japanese patients 
with RA treated with inﬂ  iximab during the 52-week course of 
this study. This result is consistent with previous studies show-
ing that the incidence of infusion reactions to inﬂ  iximab was 
approximately 10–23% of patients with RA per year.    5   –    7        8        15    
The most frequent manifestations of the infusion reactions 
observed in this study were consistent with those reported for 
infusion reactions to inﬂ  iximab in clinical practice settings in 
both the USA    5    and Japan.    8    A signiﬁ  cant proportion of these 
patients subsequently discontinued infusion, implying that 
infusion reactions may account, as well as lack of efﬁ  cacy, for 
the low retention rate of inﬂ  iximab observed in the ﬁ  rst year 
of treatment,    9        19   –    21    while others do not.    22        23    The inconsistency 
of the retention rate for inﬂ  iximab among studies may result 
from the variable management strategies used to reduce infu-
sion reactions, which include premedication,    5    gradual increases 
in infusion speed,    7    adjustment of infusion intervals    24    and dose 
increments,    25    among others. 
  It has been shown using radiolabelled inﬂ  iximab in patients 
with RA that the formation of inﬂ  iximab and anti-inﬂ  iximab 
complexes were found in non-responders, one of which showed 
an anaphylactoid reaction, resulting in higher liver/spleen uptake 
and rapid clearance of inﬂ  iximab.    11    It was recently observed that 
the IgE class of AIA is associated with the development of severe 
infusion reactions,    26    whereas true IgE-mediated hypersensitiv-
ity is not related to acute infusion reactions in most cases.    27    This 
possibility in one patient who developed an anaphylactoid reac-
tion in this cohort remains to be addressed. 
  Figure  1         Percentage of patients with rheumatoid arthritis who 
developed an infusion reaction during the 52-week study in those with 
or without anti-inﬂ  iximab antibody, those with or without   FCGR3B  
NA1/NA1 genotype and those with or without concomitant use of 
glucocorticoids.    
  Table  3      Association  of  Fcγ receptor polymorphism and anti-inﬂ  iximab antibody (AIA) with inﬂ  iximab-related 
outcome  
 Subject 
 Total 
(n=96) 
  Infusion reaction during 
52 weeks 
 p  Value 
  Adherence to inﬂ  iximab during 
52 weeks 
 p  Value 
 Yes 
(n=17) 
 No 
(n=79) 
 Continued 
(n=46) 
 Discontinued 
(n=50) 
  FCGR3A   176F/V
  F/F 44 (46)   7 (41) 37 (47) 0.58 22 (48) 22 (44) 0.53
  F/V 46 (48)   8 (47) 38 (48) 20 (44) 26 (52)
  V/V  6  (6)  2  (12)  4  (5)  4  (9)  2  (4)
  FCGR3B   NA1/NA2
  NA1/NA1 42 (44) 13 (77) 29 (37) 0.01* 16 (35) 26 (52) 0.23
  NA1/NA2 32 (33)   3 (18) 29 (37) 18 (39) 14 (28)
  NA2/NA2 22 (23)   1 (6) 21 (27) 12 (26) 10 (20)
AIA
  (+) 18 (19) 11 (65)   7 (9) <0.01*   7 (15) 11 (22) 0.40
 (−) 78 (81)  6  (35) 72 (91)   39 (85) 39 (78)  
      Values are numbers (%) unless otherwise indicated.     
  Table  4         Univariate logistic regression analysis for potential predictors 
of infusion reaction   
 Variables   Estimates   SE   OR   p  Value 
Age (years) −0.02 0.02 0.98 0.37
Gender (female vs male) 0.24 0.40 1.62 0.55
Duration (years) 0.04 0.03 1.04 0.12
DAS28 0.08 0.21 1.08 0.69
CRP (mg/dl) 0.01 0.08 1.01 0.87
MMP-3 (per 10 ng/ml) −0.01 0.01 0.99 0.55
HAQ-DI −0.12 0.39 0.89 0.75
RF (per 10 IU/ml) 0.01 0.00 1.00 0.14
ANA (×) 0.00 0.00 1.00 0.46
MTX (mg/week) 0.03 0.09 1.03 0.77
MTX duration (months) 0.00 0.01 1.00 0.72
Use of glucocorticoids −0.63 0.28 0.53 0.03*
Dose of prednisolone (mg/day) −0.13 0.09 0.88 0.14
  FCGR3A   V/V+V/F vs F/F 0.11 0.27 1.12 0.67
  FCGR3B   NA1/1 vs NA1/2+2/2 0.86 0.31 2.37 <0.01*
      ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joint Disease Activity 
Score; HAQ-DI, Health Assessment Questionnaire-Disease Index; MMP, matrix 
metalloproteinase; MTX, methotrexate; RF, rheumatoid factor.     
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to demonstrate an association between   FCGR3A   polymorphism 
and infusion reactions. Second, in addition to the small num-
ber of patients, other aspects of the study design also imposed 
limitations. For example, the study was designed to monitor 
infusion reactions during 52 weeks, meaning that infusion reac-
tions appearing after 52 weeks could not be addressed. Third, 
this was an open-label study which may have affected the inci-
dence and severity of infusion reactions and the response and 
retention rates. However, the incidence and the types of infu-
sion reactions in this study were comparable to those of previ-
ous reports, as were the other results related to the efﬁ  cacy and 
retention rate of inﬂ  iximab.    37        38    Also, AIA is typically developed 
during the treatment period and this information would not be 
available before starting inﬂ  iximab; it is apparent that the pres-
ence of AIA is limited in its use as a predictive marker. When the 
two risk factors excluding AIA are used as predictive variables, 
they were still associated with approximately 40% of infusion 
reactions observed in this study (data not shown). 
  In summary, we have shown that the   FCGR3B   NA1/NA1 
genotype and the absence of glucocorticoid usage are predictive 
factors of infusion reactions in patients with RA. Premedication 
for inﬂ  iximab may therefore not be necessary for all patients but 
only for those with the   FCGR3B   NA1/NA1 genotype without 
daily glucocorticoids.     
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